Atlas Trials

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

Clinical trial NCT07038915 · WITHDRAWN

Trial details

NCT number
NCT07038915
Sponsor
M.D. Anderson Cancer Center
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Squamous Cell CarcinomaAnti-PD1/PDL1 Antibody
Start date
2025-07-28
Primary completion
2025-07-28
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.